A combination of two metabolic inhibitors, metformin, which targets mitochondrial respiration, and 2DG, an inhibitory glucose analog, has therapeutic effects in vivo in mice and in vitro with human SLE CD4+ T cells20,21. The gene discussed is CD4; the disease is systemic lupus erythematosus.